AbCellera Biologics Inc.
Historical Data
View all| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 3, 2026 | $24.19 | $25.13 | $22.34 | $23.42 | 20.77M |
| Jul 2, 2026 | $24.15 | $24.32 | $24.03 | $24.19 | 20.90M |
| Jul 1, 2026 | $23.56 | $24.56 | $22.91 | $24.15 | 29.65M |
| Jun 30, 2026 | $23.14 | $23.96 | $22.78 | $23.56 | 24.80M |
| Jun 29, 2026 | $23.30 | $23.52 | $22.49 | $23.14 | 41.56M |
| Jun 28, 2026 | $24.65 | $25.06 | $22.79 | $23.30 | 16.57M |
| Jun 27, 2026 | $25.34 | $25.82 | $24.50 | $24.65 | 29.91M |
| Jun 26, 2026 | $25.39 | $25.52 | $25.08 | $25.34 | 16.67M |
Company Overview
AbCellera Biologics Inc. operates in the real estate space within the Real Estate sector. The company generates the majority of its revenue from operating momentum, and has built a durable competitive position through scale, brand, and continued reinvestment. It serves customers globally and is headquartered in the United States. Reported figures on this page are generated for demonstration and are not investment advice.
Leadership
Board 12 · Independent 11 of 12| Date | Firm | Target | Rating |
|---|---|---|---|
| Jun 25 | Truist Financial | — | Strong Buy |
| Jun 2 | KeyBanc | $35.21 | Hold |
| May 25 | Rosenblatt | $31.39 | Strong Buy |
| May 23 | JPMorgan | $27.87 | Hold |
| May 15 | BofA Securities | $28.29 | Reduce |
| May 8 | Goldman Sachs | $21.46 | Reduce |
Politician Trades
View allWhat's Happening Right Now
- Aug 25, 2026 · Clinical Data ↗ — ABCL stock surged after ABCL635 data reset expectations for the hot-flash treatment market.
- Aug 15, 2026 · Product ↗ — Shares soared 64% as the drug candidate's data pointed to a large potential market opportunity.
- Aug 13, 2026 · Financing ↗ — AbCellera priced an oversubscribed $200 million public offering of common shares and pre-funded warrants.
- Aug 14, 2026 · Partnership ↗ — A deal with Vertex Pharmaceuticals is being viewed as a potential catalyst to turn AbCellera's TCE platform into a breakthrough.
- Aug 14, 2026 · Insider Buying ↗ — CFO Andrew Booth acquired 37,200 shares at $10.32 each, alongside a director purchase, signaling insider confidence.
Snapshot
AbCellera Biologics has no Form 10-K on file, so no verifiable revenue, profit, or balance-sheet figures are currently available for the company. Recent attention has centered on clinical data for its ABCL635 candidate targeting the hot-flash market, which drove a sharp rally in the stock, including a 64% single-day surge and a run to a 52-week high near $11.51-$12.01. The company also raised capital via an oversubscribed $200 million public offering of common shares and pre-funded warrants, and disclosed notable insider share purchases by its CFO and a director in the $10.32-$10.37 range. A partnership involving Vertex Pharmaceuticals is being discussed as a potential avenue for AbCellera's T-cell engager (TCE) platform. In the absence of disclosed financials, the investment case currently rests on pipeline catalysts, financing activity, and market sentiment rather than reported fundamentals.
Bottom Line
With no audited financial statements on file, ABCL is effectively a binary, catalyst-driven biotech story rather than a fundamentals-based investment right now. The recent ABCL635 data surge, fresh $200M capital raise, and insider buying suggest growing confidence in the pipeline and platform (including the Vertex TCE collaboration), but the stock's sharp price swings and lack of disclosed revenue or balance-sheet data mean risk remains elevated and largely speculative. Investors are essentially betting on clinical and partnership momentum continuing before any financial substantiation is available.